Current Bms News and Events

Current Bms News and Events, Bms News Articles.
Sort By: Most Relevant | Most Viewed
Page 1 of 5 | 195 Results
Immunotherapy -- targeted drug combination improves survival in advanced kidney cancer
Patients with advanced kidney cancer, who received a targeted drug combined with a checkpoint-blocker immunotherapy agent had longer survival than patients treated with the standard targeted drug, said an investigator from Dana-Farber Cancer Institute, reporting results from a phase 3 clinical trial. (2021-02-13)

Opportunities to better detect, manage and treat patients with undiagnosed atrial fibrillation
Atrial fibrillation (AF) is associated with a higher risk of complications including ischemic stroke, cognitive decline, heart failure, myocardial infarction and death. AF frequently is undetected until complications such as stroke or heart failure occur. A new report led by Boston University School of Medicine (BUSM) researcher Emelia J. Benjamin, MD, ScM, builds upon a recently conducted National Heart, Lung, and Blood Institute's virtual workshop that focused on identifying key research priorities related to AF screening. (2021-01-25)

Hackensack University Medical Center cancer specialist demonstrates safety of novel agent
The findings, published in the online edition of Clinical Cancer Research on Nov. 4, 2020, suggest that BMS-986178, an investigational OX40 agonist, has an acceptable safety profile in patients with advanced solid tumors, whether used as monotherapy or in combination with the checkpoint inhibitors nivolumab (Opdivo®) and/or ipilimumab (Yervoy®). (2020-11-30)

New first-line treatment option for metastatic kidney cancer
The results of the phase 3 CheckMate 9ER trial have provided a new first-line treatment option for patients with metastatic kidney cancer. The late breaking results are presented at ESMO 2020. (2020-09-19)

Immunotherapy combination improves outcomes in advanced kidney cancer
An immunotherapy agent combined with a tyrosine kinase inhibitor drug significantly improved progression-free survival and reduced the risk of death compared to a single agent treatment in advanced kidney cancer patients, according to first results of a phase 3 clinical trial. The pivotal study could lead to a new treatment option for patients with metastatic kidney cancer. (2020-09-19)

Access to cancer medicines and clinical trials show stark variations across Europe
Access to cancer medicines is highly unequal across Europe both for new drugs in development because of uneven access to clinical trials and for currently approved drugs due to huge disparities in healthcare spending by different countries, according to results from studies presented at ESMO 2020. (2020-09-17)

CityU's CRISPR-assisted novel method detects RNA-binding proteins in living cells
A research led by biomedical scientists from City University of Hong Kong (CityU) has developed a novel detection method, called CARPID, to identify binding proteins of specific RNAs in the living cells. It is expected the innovation can be applied in various cell researches, from identifying biomarkers of cancer diagnosis to detecting potential drug targets for treating viral diseases. (2020-07-01)

Case series: Teriflunomide therapy in COVID-19 patients with MS
Co-authors present the cases of five multiple sclerosis patients who developed COVID-19 infection while taking the oral disease-modifying therapy teriflunomide and continued taking the medication. All five patients had favorable outcomes, with their COVID-19 taking a mild course and without experiencing relapse of their MS. (2020-06-12)

Intracellular biopsy technique for fast microRNAs profiling in living cells
MicroRNAs (miRNAs) are gaining more attention in researches. To achieve fast and highly sensitive profiling of miRNAs, a research team from City University of Hong Kong (CityU) has developed a novel high-throughput intracellular biopsy technique that isolates targeted miRNAs from living cells within around 10 minutes by using diamond nanoneedles. The technique is simple and can be applied to other aspects, from the nucleic acid testing of viruses (e.g. COVID-19) to early cancer diagnosis. (2020-06-10)

Using genetically engineered, barcoded microbes to track food contamination and more
Synthetic spores programmed with DNA barcodes provide a highly flexible, high-resolution system for tagging and tracking the provenance of an object. (2020-06-04)

Multi-drug regimen for heart failure could meaningfully extend patients' lives
A team led by investigators from Brigham and Women's Hospital has conducted an analysis to estimate the potential benefits of using a comprehensive regimen for heart failure patients compared to using a more conventional regimen, finding that comprehensive therapy could extend lifespan up to six years and eight years free from cardiovascular death or first hospital admission for heart failure. (2020-05-21)

African-American and white women share genes that increase breast cancer risk
The same genes that greatly increase the risk of breast cancer in US white women, including women of Ashkenazi Jewish descent, also greatly increase breast cancer risk among African-American women. (2020-05-19)

Palbociclib is safe for women with advanced breast cancer who have unique gene alteration
When FDA approved palbociclib (Ibrance ®), there was very little data about the safety of this drug in people with benign ethnic neutropenia (BEN), which is common in women of color. Some of these women didn't qualify for the clinical trials because of the required blood count, which is lower in women with BEN. Dr. Lynce initiated this study to make sure women of color can safely receive this important therapy and in fact, they can. (2019-12-09)

Immunotherapy is safe following chemoradiotherapy for women with node-positive cervical cancer
Results from the NRG Oncology phase I clinical trial NRG-GOG 9929 show that utilizing the immunotherapy drug ipilimumab after chemoradiotherapy (CRT) is tolerated in the curative treatment of women with lymph node-positive cervical cancer. (2019-11-27)

33% of people on anticoagulants take OTC supplements with potentially serious interactions
Nearly 98% percent of people prescribed direct-acting oral anticoagulants such as apixaban used over-the-counter products. Of those, 33% took at least one such product that, in combination with the anticoagulants, could cause dangerous internal bleeding. People on these medications largely lacked knowledge of some potentially serious interactions. Direct-acting oral anticoagulants are the drug of choice for stroke prevention in patients with atrial fibrillation, which occurs most frequently in older patients. (2019-10-28)

Resistance to immune checkpoint blocker drug linked to metabolic imbalance
A metabolic imbalance in some cancer patients following treatment with a checkpoint inhibitor drug, nivolumab, is associated with resistance to the immunotherapy agent and shorter survival, report scientists from Dana-Farber Cancer Institute. (2019-09-25)

Diabetes and heart attack is a particularly risky combination
Paris, France - 3 Sept 2019: After a heart attack, patients with diabetes are at greater risk of heart failure and subsequent death than those without diabetes, according to late breaking results from the FAST-MI registry presented today at ESC Congress 2019 together with the World Congress of Cardiology.(1) (2019-09-03)

Superbug virulence regulatory mechanism revealed: Pave ways for developing new antibiotics
As antibiotic resistance is growing and posing a threat on public health, developing new antibiotics has become more urgent than ever. Researchers at City University of Hong Kong (CityU) have recently revealed the virulence regulatory mechanism in Pseudomonas aeruginosa, a superbug which is common in patients with a weak immune system and is resistant to many antibiotics. The findings pave ways for identifying good antibiotic targets for new drug development. (2019-07-03)

Are you sure it's burning mouth syndrome?
Not all burning mouths are the result of a medical condition known as 'burning mouth syndrome' (BMS) and physicians and researchers need better standards for an appropriate diagnosis, according to new research at the School of Dental Medicine at Case Western Reserve University. (2019-07-03)

Technology allows researchers to see patients' real-time pain while in the clinic
Many patients, especially those who are anesthetized or emotionally challenged, cannot communicate precisely about their pain. (2019-06-27)

Study: New drug regimens improve outcomes for kidney transplant patients
Preliminary results from a $5.2 million clinical trial led by University of Cincinnati researchers show that the immunosuppressive drug belatacept can help safely and effectively treat kidney transplant patients without the negative long-term side effects of traditional immunosuppressive regimens, the study's leaders announced this week at the annual American Transplant Congress gathering. (2019-06-05)

Patient groups untested in cancer immunotherapy trials found to also benefit
Cancer patients previously excluded and underrepresented in immunotherapy clinical trials, such as African Americans and patients with HIV or viral hepatitis, actually benefit at the same rate as patients tested in the clinical trials, according to a Georgetown-led study to be presented at the 2019 ASCO Annual Meeting in Chicago. (2019-05-30)

Glecaprevir/pibrentasvir is effective and well tolerated in individuals with hepatitis C
Two large 'real-world' studies conducted in Germany and the USA have confirmed the high rates of sustained virological response (SVR) observed in controlled clinical studies of glecaprevir/pibrentasvir (G/P) involving individuals with hepatitis C virus (HCV) infection. (2019-04-11)

Data from two KEYNOTE trials show pembrolizumab benefited patients with advanced SCLC
The anti-PD-1 monoclonal antibody pembrolizumab (Keytruda) showed promising antitumor activity with durable responses in patients with pretreated, advanced small cell lung cancer (SCLC), according to results from a pooled analysis of the two clinical trials, the phase 1b KEYNOTE-028 and the phase II KEYNOTE-158, presented at the AACR Annual Meeting 2019, March 29-April 3. (2019-04-01)

Rare cancers: A growing focus of early-stage clinical trials
The proportion of early-stage drug trials tackling the biggest cancer killers has declined sharply since the early 1990s as less common tumour types receive increasing attention, according to new research to be presented during the International Congress on Targeted Anticancer Therapies (TAT) 2019, taking place Feb. 25-27 in Paris, France. The analysis highlights the changing treatment landscape, with doctors and pharmaceutical companies evaluating an expanding range of molecularly targeted anticancer drugs and immunotherapy. (2019-02-25)

First line immunotherapy combination fails to improve overall survival in lung cancer
First line immunotherapy with durvalumab or the combination of durvalumab and tremelimumab does not improve overall survival in unselected patients with lung cancer, according to late breaking results from the MYSTIC trial presented at the ESMO Immuno-Oncology Congress. (2018-12-13)

Shortcut strategy for screening compounds with clinical potentials for drug development
The journey of developing a new drug often takes years and needs hundreds of millions of dollars. A 'shortcut' has now been found by a collaborated research led by City University of Hong Kong (CityU), which can potentially reduce the time and costs of developing new drugs by sorting out the high potential candidates out of a long list of chemical compounds. (2018-12-03)

Immunotherapy may become new first line treatment in some metastatic colorectal cancers
Immunotherapy with nivolumab and low-dose ipilimumab could become a new first line treatment in patients with some metastatic colorectal cancers following late-breaking results from the CheckMate-142 trial reported at the ESMO 2018 Congress in Munich. The drug combination shrank tumours and had beneficial effects on survival in patients with microsatellite instabiliy (MSI)-high metastatic colorectal cancer. (2018-10-22)

Avelumab plus axitinib significantly improve PFS in untreated renal cell carcinoma
A combination of the immune checkpoint blocker, avelumab, plus the tyrosine kinase inhibitor (TKI), axitinib, significantly improves progression-free survival (PFS) in previously untreated patients with advanced renal cell carcinoma (RCC) in a phase 3 study, according to results presented at ESMO 2018 Congress. (2018-10-21)

Immune therapy generates promising results in hard-to-treat ankylosing spondylitis
Results from a phase 3 clinical trial indicate that patients who have not benefited from standard therapy for ankylosing spondylitis (AS), a chronic inflammatory disease characterized by back pain and sacroiliac-joint damage, may have another treatment option in the biologic drug ixekizumab. (2018-10-20)

Increased the performance and lifetime of lithium batteries in renewable energy facilities
Variations in power generation using renewable sources lead to control problems in the electricity grid. The technology of lithium batteries is a candidate offering great potential in solving these problems. An industrial engineer at the Public University of Navarre (NUP/UPNA) has developed a new management system that allows good performance of these batteries to be achieved and their lifetime to be preserved when connected to a renewable facility to store the electrical energy produced. (2018-09-18)

New soft coral species discovered in Panama
Another new coral found in Panama's Coiba National Park, a UNESCO National Heritage Site, the location of the Smithsonian's newest research site. (2018-09-14)

Enhancing immune checkpoint inhibitor therapy using treatment combination
A combination of a novel inhibitor of the protein CK2 (Casein kinase 2) and an immune checkpoint inhibitor has dramatically greater antitumor activity than either inhibitor alone, according to research from The Wistar Institute that was published online in Cancer Research. (2018-09-05)

BIDMC researchers develop decision-making tool to benefit patients with HCV
BIDMC researchers led a retrospective analysis of four randomized clinical trials focused on the effects of DAA therapies in patients with HCV-associated liver failure, and developed a new means of predicting improvement in liver function in response to DAA treatment. (2018-06-18)

New approach to cancer research aims to accelerate studies and reduce cost
A new model for improving how clinical trials are developed and conducted by bringing together academic cancer experts and pharmaceutical companies is being tested by research experts at The University of Texas MD Anderson Cancer Center. (2018-05-14)

Long-term obeticholic acid treatment leads to reversal or stabilization of fibrosis/cirrhosis in patients with PBC
After three years of treatment with obeticholic acid, 85 percent of patients with PBC and an incomplete response to UDCA experienced stabilization or regression of fibrosis/cirrhosis in the POISE biopsy sub-study. (2018-04-13)

Researchers develop new approach that uses single PET scan to personalize cancer treatment
Researchers have developed a same-day, noninvasive PET-based imaging approach to assess PD-L1 positive tumors, which could help guide cancer treatment decisions and assess treatment response. The study is presented in the featured article of The Journal of Nuclear Medicine's March issue. (2018-03-01)

Cancer immunotherapy may work better in patients with specific genes
Investigators have been trying to understand why and have recently found how an individual's own genes can play a role in the response to the immunotherapy drugs. (2017-12-14)

Synergy stent with shorter DAPT is superior to a bare-metal stent in elderly patients
Elderly patients undergoing PCI often receive bare-metal stents (BMS) instead of drug-eluting stents (DES) to shorten the duration of dual antiplatelet therapy (DAPT) and reduce bleeding risk. However, results from the SENIOR trial found that compared with BMS, shorter DAPT combined with the Synergy bioabsorbable polymer DES leads to less adverse events without increasing bleeding risk. (2017-11-02)

When two is better than three: Dual antithrombotic therapy cuts bleeding risk
Clinical trial finds that dabigatran dual therapy after stenting reduced bleeding risk for patients with atrial fibrillation compared with standard triple therapy. (2017-08-27)

Page 1 of 5 | 195 Results
   First   Previous   Next      Last is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to